Assessment of extracranial metastatic disease in patients with brain metastases: How much effort is needed in the context of evolving survival prediction models?

C. Nieder*, M.P. Mehta, M. Guckenberger, L.E. Gaspar, C.G. Rusthoven, A. Sahgal, A.L. Grosu, D. De Ruysscher

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

3 Citations (Web of Science)

Abstract

Survival prediction models may serve as decision-support tools for clinicians who have to assign the right treatment to each patient, in a manner whereby harmful over- or undertreatment is avoided as much as possible. Current models differ regarding their components, the overall number of components and the weighting of individual components. Some of the components are easy to assess, such as age or primary tumor type. Others carry the risk of inter-assessor inconsistency and time-dependent variation. The present publication focuses on issues related to assessment of extracranial metastases and potential surrogates, e.g. blood biomarkers. It identifies areas of controversy and provides recommendations for future research projects, which may contribute to prognostic models with improved accuracy. (c) 2021 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 159 (2021) 17-20
Original languageEnglish
Pages (from-to)17-20
Number of pages4
JournalRadiotherapy and Oncology
Volume159
DOIs
Publication statusPublished - 1 Jun 2021

Keywords

  • Brain metastases
  • Extracranial metastases
  • Prognostic score
  • Radiotherapy
  • Survival prediction
  • GRADED PROGNOSTIC ASSESSMENT
  • PERFORMANCE STATUS ASSESSMENT
  • CELL LUNG-CANCER
  • STEREOTACTIC RADIOSURGERY
  • OLIGOMETASTATIC DISEASE
  • SUPPORTIVE CARE
  • RECOMMENDATIONS
  • RADIOTHERAPY
  • BIOMARKER
  • PHASE-3

Cite this